Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects

Hajnalka Lórincz, Mõnika Katkõ, Mariann Harangi, Sándor Somodi, Krisztina Gaál, Péter Fülöp, György Paragh, Ildikõ Seres

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective Chemerin is a recently described adipokine expressed primarily in the white adipose tissue. Compared with lean subjects, circulating chemerin levels are significantly elevated in obese individuals and correlate positively with the prevalence of various cardiovascular risk factors including altered lipoprotein levels. To date, the impact of chemerin on lipoprotein subfractions and its role in atherosclerotic processes are still unclear. Patients and Methods Fifty nondiabetic obese (NDO) patients and 38 lean controls matched in age and gender were enrolled. Chemerin level was measured by ELISA. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions were detected by nongradient polyacrylamide gel electrophoresis (Lipoprint). Results We detected significantly higher serum chemerin levels in NDO patients compared with healthy controls (590·1 ± 190·3 ng/ml vs 405 ± 127·1 ng/ml, P <0·001). A significant positive correlation was found between chemerin and LDL cholesterol levels, while chemerin showed a significant negative correlation with the level of HDL cholesterol. Significant positive correlation was detected between chemerin and the ratio of small dense LDL, while chemerin correlated negatively with the mean LDL size. Also, a significant negative correlation was found between serum chemerin and the ratio of large HDL subfraction, while there were significant positive correlations between chemerin levels and intermediate and small HDL subfraction ratios, respectively. Conclusion Chemerin may be involved in the regulation of lipoprotein metabolism in obese patients who do not show apparent abnormalities of glucose metabolism. Early changes in the distribution of the lipoprotein subfractions may contribute to the progression of atherosclerosis, leading to increased cardiovascular risk.

Original languageEnglish
Pages (from-to)370-377
Number of pages8
JournalClinical Endocrinology
Volume81
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Lipoproteins
HDL Lipoproteins
LDL Lipoproteins
White Adipose Tissue
Adipokines
Serum
LDL Cholesterol
HDL Cholesterol
Polyacrylamide Gel Electrophoresis
Atherosclerosis
Enzyme-Linked Immunosorbent Assay
Glucose

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects. / Lórincz, Hajnalka; Katkõ, Mõnika; Harangi, Mariann; Somodi, Sándor; Gaál, Krisztina; Fülöp, Péter; Paragh, György; Seres, Ildikõ.

In: Clinical Endocrinology, Vol. 81, No. 3, 2014, p. 370-377.

Research output: Contribution to journalArticle

Lórincz, Hajnalka ; Katkõ, Mõnika ; Harangi, Mariann ; Somodi, Sándor ; Gaál, Krisztina ; Fülöp, Péter ; Paragh, György ; Seres, Ildikõ. / Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects. In: Clinical Endocrinology. 2014 ; Vol. 81, No. 3. pp. 370-377.
@article{dc1f8e97094043d9aaf4c85269cd064a,
title = "Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects",
abstract = "Objective Chemerin is a recently described adipokine expressed primarily in the white adipose tissue. Compared with lean subjects, circulating chemerin levels are significantly elevated in obese individuals and correlate positively with the prevalence of various cardiovascular risk factors including altered lipoprotein levels. To date, the impact of chemerin on lipoprotein subfractions and its role in atherosclerotic processes are still unclear. Patients and Methods Fifty nondiabetic obese (NDO) patients and 38 lean controls matched in age and gender were enrolled. Chemerin level was measured by ELISA. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions were detected by nongradient polyacrylamide gel electrophoresis (Lipoprint). Results We detected significantly higher serum chemerin levels in NDO patients compared with healthy controls (590·1 ± 190·3 ng/ml vs 405 ± 127·1 ng/ml, P <0·001). A significant positive correlation was found between chemerin and LDL cholesterol levels, while chemerin showed a significant negative correlation with the level of HDL cholesterol. Significant positive correlation was detected between chemerin and the ratio of small dense LDL, while chemerin correlated negatively with the mean LDL size. Also, a significant negative correlation was found between serum chemerin and the ratio of large HDL subfraction, while there were significant positive correlations between chemerin levels and intermediate and small HDL subfraction ratios, respectively. Conclusion Chemerin may be involved in the regulation of lipoprotein metabolism in obese patients who do not show apparent abnormalities of glucose metabolism. Early changes in the distribution of the lipoprotein subfractions may contribute to the progression of atherosclerosis, leading to increased cardiovascular risk.",
author = "Hajnalka L{\'o}rincz and M{\~o}nika Katk{\~o} and Mariann Harangi and S{\'a}ndor Somodi and Krisztina Ga{\'a}l and P{\'e}ter F{\"u}l{\"o}p and Gy{\"o}rgy Paragh and Ildik{\~o} Seres",
year = "2014",
doi = "10.1111/cen.12363",
language = "English",
volume = "81",
pages = "370--377",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects

AU - Lórincz, Hajnalka

AU - Katkõ, Mõnika

AU - Harangi, Mariann

AU - Somodi, Sándor

AU - Gaál, Krisztina

AU - Fülöp, Péter

AU - Paragh, György

AU - Seres, Ildikõ

PY - 2014

Y1 - 2014

N2 - Objective Chemerin is a recently described adipokine expressed primarily in the white adipose tissue. Compared with lean subjects, circulating chemerin levels are significantly elevated in obese individuals and correlate positively with the prevalence of various cardiovascular risk factors including altered lipoprotein levels. To date, the impact of chemerin on lipoprotein subfractions and its role in atherosclerotic processes are still unclear. Patients and Methods Fifty nondiabetic obese (NDO) patients and 38 lean controls matched in age and gender were enrolled. Chemerin level was measured by ELISA. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions were detected by nongradient polyacrylamide gel electrophoresis (Lipoprint). Results We detected significantly higher serum chemerin levels in NDO patients compared with healthy controls (590·1 ± 190·3 ng/ml vs 405 ± 127·1 ng/ml, P <0·001). A significant positive correlation was found between chemerin and LDL cholesterol levels, while chemerin showed a significant negative correlation with the level of HDL cholesterol. Significant positive correlation was detected between chemerin and the ratio of small dense LDL, while chemerin correlated negatively with the mean LDL size. Also, a significant negative correlation was found between serum chemerin and the ratio of large HDL subfraction, while there were significant positive correlations between chemerin levels and intermediate and small HDL subfraction ratios, respectively. Conclusion Chemerin may be involved in the regulation of lipoprotein metabolism in obese patients who do not show apparent abnormalities of glucose metabolism. Early changes in the distribution of the lipoprotein subfractions may contribute to the progression of atherosclerosis, leading to increased cardiovascular risk.

AB - Objective Chemerin is a recently described adipokine expressed primarily in the white adipose tissue. Compared with lean subjects, circulating chemerin levels are significantly elevated in obese individuals and correlate positively with the prevalence of various cardiovascular risk factors including altered lipoprotein levels. To date, the impact of chemerin on lipoprotein subfractions and its role in atherosclerotic processes are still unclear. Patients and Methods Fifty nondiabetic obese (NDO) patients and 38 lean controls matched in age and gender were enrolled. Chemerin level was measured by ELISA. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions were detected by nongradient polyacrylamide gel electrophoresis (Lipoprint). Results We detected significantly higher serum chemerin levels in NDO patients compared with healthy controls (590·1 ± 190·3 ng/ml vs 405 ± 127·1 ng/ml, P <0·001). A significant positive correlation was found between chemerin and LDL cholesterol levels, while chemerin showed a significant negative correlation with the level of HDL cholesterol. Significant positive correlation was detected between chemerin and the ratio of small dense LDL, while chemerin correlated negatively with the mean LDL size. Also, a significant negative correlation was found between serum chemerin and the ratio of large HDL subfraction, while there were significant positive correlations between chemerin levels and intermediate and small HDL subfraction ratios, respectively. Conclusion Chemerin may be involved in the regulation of lipoprotein metabolism in obese patients who do not show apparent abnormalities of glucose metabolism. Early changes in the distribution of the lipoprotein subfractions may contribute to the progression of atherosclerosis, leading to increased cardiovascular risk.

UR - http://www.scopus.com/inward/record.url?scp=84905126660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905126660&partnerID=8YFLogxK

U2 - 10.1111/cen.12363

DO - 10.1111/cen.12363

M3 - Article

C2 - 24303851

AN - SCOPUS:84905126660

VL - 81

SP - 370

EP - 377

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -